RxDoctor Payments Data

Vikram Prasad, MD

Internal Medicine · Philadelphia, PANPI 1740693548

Payments from drug & device makers

$41,295in general payments, 2019–2025

Across 209 payments — averaging $197.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$22K
  • Abbott$4K
  • Philips North America LLC$4K
  • Abiomed$3K
  • Edwards Lifesciences$2K
  • Ancora Heart, Inc.$2K
  • plus $4K from 18 others
$263in research payments, 2019–2025

Across 3 payments — averaging $87.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$263

What the payments were for

  • Grants$20,00048%
  • Travel & lodging$14,31135%
  • Food & beverage$5,89514%
  • Education$1,0062%
  • Gifts$840%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,295 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$189,816
Medicare patients
2,671
Services billed
5,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban64$69,878
JardianceEmpagliflozin40$46,499
EntrestoSacubitril/Valsartan16$22,406
Repatha SureclickEvolocumab21$15,808
BrilintaTicagrelor19$15,307
Metoprolol Succinate137$1,298
Ezetimibe44$994
Atorvastatin Calcium102$880
ClopidogrelClopidogrel Bisulfate52$508
Losartan Potassium79$442
Nifedipine ErNifedipine11$345
Potassium Chloride32$345
Amlodipine Besylate47$303
Spironolactone43$196
Metoprolol Tartrate41$172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$41$69,87864 claims
NovartisEntresto$23$22,40616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →